Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001104659-26-097275
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$3.86M | -$2.90M | -$2.54M | -$5.33M |
| EPS Diluted | -$0.35 | -$0.34 | -$0.60 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
